Skip to main content

NAUT

Stock
Health Care
Biotechnology

Performance overview

NAUT Price
Price Chart

Forward-looking statistics

Beta
0.93
Risk
62.96%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. It has built a prototype of a single-molecule instrument, Proteomic Analysis System.

Company info

SectorHealth Care
IndustryBiotechnology
Employees168
Market cap$325.7M

Fundamentals

Enterprise value-$18.0M
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity15.09

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.54
Dividend per share
Revenue per share
Avg trading volume (30 day)$327K
Avg trading volume (10 day)$670K
Put-call ratio

Macro factor sensitivity

Growth+3.1
Credit+6.9
Liquidity-4.6
Inflation-1.9
Commodities-0.3
Interest Rates-0.0

Valuation

Dividend yield0.00%
PEG Ratio-1.11
Price to sales
P/E Ratio-1.11
Enterprise Value to Revenue
Price to book0.53

Upcoming events

Next earnings dayApril 29, 2025
Next dividend day
Ex. dividend day

News

Nautilus Biotechnology (NAUT) Upgraded to Buy: Here's What You Should Know

Nautilus Biotechnology (NAUT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research (May 3, 2024)
Jim Cramer considers the investment cases for Nautilus Biotechnology and Cyxtera Technologies

On Friday's episode of "Mad Money," host Jim Cramer reviewed the investment cases for Nautilus Biotechnology and Cyxtera Technologies, two companies that viewers had previously called about in search of advice.

CNBC Television (January 22, 2022)
Why Nautilus Biotechnology (NAUT) Stock Trading Higher Thursday?

Nautilus Biotechnology Inc (NASDAQ: NAUT) shares are trading higher during mid-day trading on Thursday following a CNBC report that Amazon.com Inc (NASDAQ: AMZN) held around $15 million stake in the company at the end of Q2. The $14.7 million investment was disclosed in a recent Amazon SEC Form 13F filing.

Benzinga (August 5, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free